|Articles|August 15, 2002

BioPharm International-08-01-2002
Volume 15
Issue 8

Virus Inactivation in the 1990s ? and into the 21st Century: Part 2, Red Blood Cells and Platelets

by Gail Sofer, BioReliance Smallest of the parasites, viruses depend completely on other cells (animal, bacterial, or vegetable) for reproduction ? several hundred viruses infect humans. Viruses can be inactivated by extremes of pH, heat, UV, desiccation, antiseptics, disinfectants, and organic solvents among others. The trick is in finding the right antiviral method for a particular virus ? without harming the biological product of interest. With Part 2 of this literature survey, we look at viral inactivation methods for RBCs and platelets.

To view a PDF of this article from the BioPharm International archives, click this link

Articles in this issue

about 24 years ago

Article

Guest Editorial: Quality Agreements with Contract Laboratories

about 24 years ago

Article

Survival Guide to FDA Inspections: Part 1, To Prepare or Not to Prepare, There Is No Question

about 24 years ago

Article

Making Regulatory Compliance a Core Process: Director and Officer Liability Exposure

about 24 years ago

Article

Inside Washington: User Fee Program Seeks to Spur Biotech Development

about 24 years ago

Article

Analytical Advances: Mapping Proteins – the 2-D Electrophoresis Issue

about 24 years ago

Article

Your Vested Interests: Gorillas In Our Midst

about 24 years ago

Article

Outsourcing Outlook: How to Engage in a Strategic Outsourcing Relationship

about 24 years ago

Article

Throughput Analysis and Debottlenecking of Biomanufacturing Facilities ? A Job for Process Simulators

Stay at the forefront of biopharmaceutical innovation. Subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.

Related to this article

October 22nd, 2026

Turn Supply Chain Data Into Decisions Before Shortages Reach Patients, Says RELEX’s Rohit Tripathi

Rohit Tripathi, vice president of industry strategy, consumer packaged goods, and manufacturing at RELEX Solutions, explains where cold-chain planning still breaks down and why biopharma supply chain leaders should use AI to act on data sooner, with humans making the final call.

October 22nd, 2026

The BioPharm Brief: Kidney Approval, Retinal Cell Therapy, and a Breast Cancer Trial Shift

The FDA grants accelerated approval to Ultomiris for IgA nephropathy, Alcon acquires Neurotech and its MacTel cell therapy for $550 million, and BioNTech and Bristol Myers Squibb add Trodelvy to a phase 3 trial in triple-negative breast cancer.

Technologist in white protective uniform controlling industrial process using tablet computer. | Image credit: © littlewolf1989 - © littlewolf1989 - stock.adobe.com

October 22nd, 2026

Zylidac Bio to Scale Prolific's Optogenetic Cell Line Platform to GMP

Zylidac will test whether optogenetic cell lines that hit 21 g/L in small-scale CHO runs can deliver higher-yield complex biologics at GMP scale.

Structure of human eye. In side view. | Image credit: © svetazi - © svetazi - stock.adobe.com

October 22nd, 2026

Alcon Pays $550 Million for Neurotech and Its MacTel Cell Therapy

Revakinagene taroretcel (Encelto), the only FDA-approved MacTel therapy, slowed photoreceptor loss by up to 54.8% vs sham in phase 3 trials.

3D cross-section illustration of breast tissue showing pink lobes, milk ducts converging toward the nipple, and a dark red clustered mass representing a tumor. | Image Credit: © Design cells - stock.adobe.com

October 22nd, 2026

BioNTech, BMS to Pair Pumitamig With Trodelvy in Phase 3 First-Line TNBC Trial

BioNTech and Bristol Myers Squibb will replace chemotherapy with Gilead’s TROP2-directed ADC sacituzumab govitecan in the Phase 3 ROSETTA Breast-01 trial of PD-L1×VEGF-A bispecific pumitamig in PD-L1-low or -negative TNBC.

A clinician in a white coat with a stethoscope points a pen at an anatomical model showing the kidneys, renal blood vessels, aorta, vena cava, and ureters. | Image Credit: © Yanisa - stock.adobe.com

October 22nd, 2026

FDA Grants Accelerated Approval to Ultomiris as First C5 Inhibitor for IgA Nephropathy

Alexion’s ravulizumab won accelerated approval to reduce proteinuria in adults with IgA nephropathy after the Phase 3 I CAN trial showed a 43.4% placebo-adjusted reduction at Week 34.

October 21st, 2026

The BioPharm Brief: Insulin Supply Security, a Bispecific Head-to-Head, and Long-Acting HIV Antibodies

Sanofi breaks ground on an EU-backed insulin API plant in Frankfurt, Summit and ECOG-ACRIN launch a phase 2/3 trial of ivonescimab in first-line biliary tract cancer, and TaiMed’s anti-CD4 antibody TMB-365 lowers HIV viral load in phase 1.

October 21st, 2026

Reshoring Should Be Judged by Risk Removed, Not Factories Moved, Says RELEX’s Rohit Tripathi

Rohit Tripathi, vice president of industry strategy, consumer packaged goods, and manufacturing at RELEX Solutions, explains what is driving biopharma reshoring, how USMCA uncertainty complicates sourcing for biologics, and where cold-chain visibility still breaks down.

Virus Inactivation in the 1990s ? and into the 21st Century: Part 2, Red Blood Cells and Platelets

Articles in this issue

Related to this article

Trending on BioPharm International

Zylidac Bio to Scale Prolific's Optogenetic Cell Line Platform to GMP

Sanofi Begins Construction of EU-Backed Insulin Plant in Frankfurt

TaiMed’s Anti-CD4 Antibody TMB-365 Reduces HIV Viral Load in Phase 1, Supporting Long-Acting Combination Regimens

Akeso's Ivonescimab Enters Phase 2/3 Biliary Tract Cancer Trial in US

BioNTech, BMS to Pair Pumitamig With Trodelvy in Phase 3 First-Line TNBC Trial